SC
DFTX

Stempoint Capital’s Definium Therapeutics DFTX Stock Holding History

Stempoint Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.15M Buy
+325,483
New +$5.52M 1.18% 29
2025
Q4 		– Sell
-76,875
Closed -$906K – 103
2025
Q3 		$906K Sell
76,875
-13,977
-15% -$130K 0.18% 64
2025
Q2 		$590K Buy
+90,852
New +$598K 0.19% 51

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stempoint Capital's DFTX Position: Q1 2026 in Review

Stempoint Capital opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 325,483 shares worth $6.15M. The stake represents 1.18% of the portfolio and ranks #29 among its holdings. This is a return to the name: Stempoint Capital previously reported a position in DFTX as recently as Q3 2025.

Stempoint Capital first reported a position in DFTX in Q2 2025 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Stempoint Capital held 325,483 shares of Definium Therapeutics worth $6.15M as of Q1 2026.
  • Definium Therapeutics was a new Stempoint Capital position in Q1 2026.
  • Definium Therapeutics made up 1.18% of Stempoint Capital's portfolio in Q1 2026, its #29 holding.
  • Stempoint Capital first reported a position in Definium Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.